OCUL Ocular Therapeutix Inc.

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, an ophthalmic device designed to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant administered by the fine-gauge needle that is in phase 1 clinical trial for the treatment of wet age-related macular degeneration; OTX-TIC, a travoprost intracameral implant, which is in phase 1 clinical trial for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that is in phase 2 clinical trial for the chronic treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trial for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company is involved in the development of OTX-AFS, an aflibercept suprachoroidal injection for the treatment of retinal diseases. It has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of Dry Age-related Macular Degeneration. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Recent Analyst Ratings for Ocular Therapeutix Inc.

Date	Price Target	Rating	Analyst
4/8/2025		Outperform	William Blair
3/18/2025	$17.00	Outperform	RBC Capital Mkts
3/11/2025	$15.00	Buy	Needham
10/16/2024		Sector Outperform	Scotiabank
6/20/2024	$7.00 → $11.00	Hold → Buy	TD Cowen
5/31/2024	$15.00	Overweight	Piper Sandler
2/9/2024	$15.00	Buy	BofA Securities
4/21/2023	$18.00	Outperform	Robert W. Baird
8/10/2022	$15.00	Buy	Berenberg
3/1/2022	$30.00 → $22.00	Market Outperform	JMP Securities

See more ratings

Ocular Therapeutix Inc.

Peers

Recent Analyst Ratings for Ocular Therapeutix Inc.

Ocular Therapeutix Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

New insider Meyers Steve Lawrence claimed ownership of 152,728 shares (SEC Form 3)

New insider Saroj Namrata claimed ownership of 200,000 shares (SEC Form 3)

SEC Form 4 filed by Officer Dugel Pravin

Director Hong Seung Suh was granted 14,000 shares, increasing direct ownership by 43% to 46,933 units (SEC Form 4)

Director Raines Merilee was granted 14,000 shares, increasing direct ownership by 43% to 46,933 units (SEC Form 4)

Director Lindstrom Richard L Md was granted 14,000 shares, increasing direct ownership by 11% to 143,145 units (SEC Form 4)

Director Williams Leslie J. was granted 14,000 shares, increasing direct ownership by 37% to 51,433 units (SEC Form 4)

Director Warden Charles M was granted 14,000 shares, increasing direct ownership by 19% to 86,464 units (SEC Form 4)

Director Graves Adrienne L was granted 14,000 shares, increasing direct ownership by 39% to 50,000 units (SEC Form 4)

Chief Medical Officer Waheed Nadia sold $111,581 worth of shares (13,861 units at $8.05), decreasing direct ownership by 6% to 206,805 units (SEC Form 4)